Goldman Sachs Alternatives served as lead investor; additional investments from BlackRock Secondaries & Liquidity SolutionsNEW YORK, June 24, 2025 /PRNewswire/ -- Avista Healthcare Partners ("Avista"), a leading private equity firm focused exclusively on healthcare, today announced the successful close of Avista Healthcare Partners CV II, L.P., a single-asset continuation fund for GCM, a leading outsourced manufacturer of complex precision components for high-growth medical technology end markets. The conti ...

June 18, 2025 05:02 PM GMT Medical Technology | North America Off the Beaten Path In this note we flag each week a handful of news drops that we think may have been missed / piqued our interest. [EW, MDT] Real-World Data in EMEA Favoring SAVR vs. TAVR In Younger Patients: A new study in Italy suggests that SAVR may be associated with more favorable mortality outcomes in intermediate surgical risk patients than TAVR, with curves decently below from about 1 year onwards (see below), which in theory is negativ ...

Core Insights - The article discusses the launch of the upgraded version of the medical reform in Luohu, Shenzhen, focusing on the establishment of a medical corpus center to enhance the integration and utilization of medical data for AI applications [1][6]. Group 1: Medical Corpus Center Development - The Luohu Medical Corpus Center aims to consolidate data from various medical institutions to support AI in healthcare, addressing challenges like data fragmentation and integration difficulties [1][2]. - The center has completed its project initiation, with ongoing construction efforts to integrate structured and unstructured data from the Luohu Hospital Group and Shenzhen People's Hospital, targeting a total data volume exceeding 3PB [2][4]. Group 2: Data Security and Privacy - A strict "data does not leave the domain" principle will be followed to ensure data security and protect personal privacy, utilizing technologies like blockchain and privacy computing to maintain control and traceability of data usage [5][10]. - An innovative model for personal medical data insurance will be explored, allowing individuals to authorize the use of their medical data, thus creating a secure and compliant data circulation mechanism [5][10]. Group 3: Collaboration and Innovation - The initiative involves collaboration among various stakeholders, including local government, hospitals, and tech companies, to foster innovation in medical AI applications and enhance the value of medical data [6][7]. - The signing of agreements between the Luohu District government and several enterprises marks a commitment to advancing the medical AI industry and promoting the standardization and circulation of medical data [7][10].

Core Insights - Solventum has been recognized among the top 25 percent of companies in healthcare and research, as well as in the Midwest, just 14 months after its formation as an independent company [1] - The company achieved a perfect score of 5/5 in three critical workplace factors: Work-Life Balance, Stability, and Belongingness, reflecting its commitment to a positive work environment [2] - The recognition is part of Solventum's successful first phase of a three-phased Transformation Plan, which emphasizes culture and employee engagement [3] Company Overview - Solventum has over 70 years of legacy innovation and focuses on providing breakthrough solutions for healthcare professionals while fostering an empowering workplace culture [4] - The U.S. News rankings evaluated over 5,000 publicly traded companies based on employee sentiment and various workplace factors, highlighting Solventum's strong performance [5] - The company aims to enable better healthcare through innovative solutions at the intersection of health, material, and data science [6]

Core Viewpoint - Smith+Nephew has announced a strategic partnership with Standard Health to develop the first Orthopaedic Ambulatory Surgery Centre in the UK, aimed at improving access to advanced joint repair and replacement technologies for both NHS and private patients [1][2]. Group 1: Partnership Details - The new centre will be located in Poole, Dorset, and is expected to open in 2025, serving thousands of patients annually, primarily through NHS referrals [3][4]. - Standard Health will manage the site development and operation, while Smith+Nephew will provide its innovative medical technologies [2][10]. - Standard Health plans to expand by opening an additional 10 sites in the UK over the next three years, totaling 20 by 2030 [2]. Group 2: Operational Model and Benefits - The centre will adopt the Ambulatory Surgery Center (ASC) model from the US, which has proven benefits such as greater procedural efficiency, a 92% patient satisfaction rate, and a 40% reduction in costs for outpatient joint replacements compared to hospital-based surgeries [3][6]. - The UK currently has over 850,000 individuals waiting for orthopaedic surgery, highlighting the need for independent providers to meet this demand [3]. Group 3: Strategic Goals - The partnership aims to redefine the UK independent care provider model for orthopaedics, ensuring a standard quality of care and long-term sustainability for NHS commissioners [4]. - The collaboration is positioned to address the significant waiting times for procedures in the UK, leveraging Smith+Nephew's expertise in ASCs to enhance patient outcomes [4][10].

Investment Rating - The report indicates a positive shift in sentiment within the healthcare sector, particularly among biopharma and MedTech companies, suggesting a constructive outlook for investment opportunities [3][6][11]. Core Insights - There is a notable constructive engagement between biopharma companies and the administration regarding drug pricing, although visibility on future actions remains low [3][7]. - The MedTech environment is characterized by robust capital expenditure and stable utilization trends, indicating a healthy operational landscape [6][11]. - Companies are actively pursuing business development and M&A opportunities, particularly in therapeutic areas like immunology and obesity [6][8]. - The report highlights a focus on upcoming catalysts and events that could influence market dynamics, including key conferences and regulatory approvals [9][19]. Summary by Sections US Pharma - Large-cap pharma companies expressed a continued appetite for business development, with a focus on immunology and internal medicine [5][6]. - Pricing dynamics in the obesity sector are under scrutiny, with companies like LLY and PFE discussing their strategies amidst evolving market conditions [8][11]. EU Pharma - Uncertainty remains regarding the timing and impact of tariffs, with companies exploring inventory management and manufacturing strategies to mitigate risks [11][12]. - The implementation of Most Favored Nation (MFN) pricing is still unclear, but companies are strategizing to protect against potential impacts [11][12]. Biotechnology - Companies like AMGN and GILD are actively engaging with policymakers to advocate for patient access and value, while also monitoring the impact of tariffs on their operations [16][18]. - The focus on M&A and business development remains strong, with companies looking for innovative opportunities to enhance their pipelines [27][28]. Key Upcoming Catalysts - Significant upcoming events include the ADA conference and various PDUFA dates, which are expected to provide critical data and insights into ongoing developments in the sector [9][19][20]. - Companies are preparing for important readouts and regulatory decisions that could shape their future growth trajectories [19][30].

Breast Cancer Statistics and Screening Challenges - Globally, breast cancer caused 670,000 deaths in 2022, with 11,500 deaths in the UK, equating to 32 deaths per day, and cases are predicted to rise to 70,000 by 2040 [1] - While death rates are falling by 44% due to interventions, better screening, and treatments, low screening uptake remains a concern, especially among underserved populations [1] - NHS backlogs, exacerbated by decades of underfunding and COVID-19, contribute to reduced resources and disproportion between screenings needed and available radiologists and mammographic equipment [1] - Accessibility problems are significantly worse for underserved populations, with cultural unacceptability, invasiveness, fear of radiation, and pain deterring women from undergoing mammography [1] - A survey revealed that 21% of 2,000 women cited embarrassment and fear of pain as reasons for avoiding screening [1] Fingerprint-Based Breast Cancer Screening Innovation - A novel fingerprint-based test is proposed as a non-invasive, radiation-free, and painless alternative to mammography, bypassing NHS backlogs and resource constraints [1] - The technology utilizes mass spectrometry (MALDI) to analyze molecular patterns in fingerprints, identifying proteins indicative of an individual's state, including potential biomarkers for breast cancer [1] - Research demonstrated the ability to differentiate between male and female fingerprints with 86% accuracy by analyzing protein profiles [2] - A study involving 135 samples from 15 women showed that a machine learning algorithm could distinguish between early breast cancer, benign conditions, and metastatic cancer with 97.8% accuracy [2] - The fingerprint test aims to reduce NHS costs, increase accessibility (potentially at GP practices or at home), improve compliance, and ultimately save lives [2]

Core Viewpoint - Myriad Genetics, Inc. is focusing on expanding its companion diagnostics and oncology business while facing challenges from the end of UnitedHealthcare's GeneSight coverage and macroeconomic pressures [1][8]. Company Performance - Myriad Genetics' shares have decreased by 79% over the past year, contrasting with a 12.6% decline in the industry and a 9.2% gain in the S&P 500 [2]. - The company has a market capitalization of $463.7 million and an earnings yield of 0.2%, outperforming the industry's -29.4% yield [2]. - Myriad Genetics has consistently surpassed earnings estimates over the last four quarters, achieving an average surprise of 210% [2]. Growth Opportunities - There is significant potential in oncology testing, particularly through partnerships and new offerings such as the integrated program with Gabbi and the addition of AI technology from PATHOMIQ [3][4]. - Myriad Genetics has seen an 11% year-over-year growth in MyRisk testing volume and plans to launch new products like the Prequel and Precise MRD tests [5]. - The women's health segment, especially MyRisk cancer screening, targets approximately 50 million women in the U.S. who meet hereditary cancer testing guidelines, with prenatal testing revenues increasing by 11% year over year [6]. Strategic Initiatives - The company is investing in electronic medical records (EMR) solutions to enhance customer and patient experiences, which is expected to drive future volume growth [9]. - Myriad Genetics has been granted two new patents for its MRD test, building on previous patents, and plans to launch the Precise MRD test in the first half of 2026 [4]. Financial Health - As of the first quarter of 2025, Myriad Genetics had cash and cash equivalents of $92 million and no short-term debt, indicating strong solvency [10]. Challenges - The end of UnitedHealthcare's coverage for the GeneSight test has resulted in a 20% year-over-year revenue decline for this product [12]. - The company faces macroeconomic pressures, including rising labor costs and tariffs, which could impact profitability [11].

June 12, 2025 02:21 PM GMT Mindray Bio-Medical | Asia Pacific M Update Takeaways from Investor Day This year's event was very well attended. The chairman shared the overall business strategy against the evolving policy/ geopolitical backdrop. The senior R&D team discussed the total solution strategy for AI integration and consumable sales. Mindray aspires to be a global top 10 medtech player. Key Takeaways Mi-Care: As Mindray's most well-established segment, Mindray launched its proprietary LLM model for cr ...

Sanara MedTech Investor Presentation Disclaimers This presentation contains forward-looking statements that discuss expectations as to future trends, plans, events, results of operations or financial condition, or state other information relating to Sanara MedTech Inc. (the "Company," "Sanara," "we," "our" or "us"). All statements other than statements of historical fact contained herein are forward-looking statements. These statements may be identified by terms such as "aims," "anticipates," "believes," "c ...